SYNALGOS-DC-A bulk active fine chemical vendors

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
Starshine Chemical	⤷ Get Started Free	2023-05-16B03899	⤷ Get Started Free
RR Scientific	⤷ Get Started Free	R6448212	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: July 29, 2025

Overview

SYNALGOS-DC-A is a proprietary drug composed primarily of a specific active pharmaceutical ingredient (API) used for its analgesic and anti-inflammatory properties. Understanding the sourcing landscape of the API is crucial for pharmaceutical companies seeking reliable supply chains, regulatory compliance, and cost optimization. This article explores the primary global sources, suppliers, and market trends associated with the bulk API used in SYNALGOS-DC-A.

Introduction to SYNALGOS-DC-A and Its API Composition

SYNALGOS-DC-A combines multiple active ingredients to deliver targeted therapeutic effects, primarily analgesia and inflammation reduction. While the exact formulation details are proprietary, the core API commonly referenced for similar formulations includes non-steroidal anti-inflammatory drugs (NSAIDs), such as Diclofenac, or other analogous compounds depending on regional formulations.

For the purpose of this analysis, the key API considered aligns with NSAID derivatives, especially Diclofenac sodium, given its prevalent use in combination products targeting pain and inflammation.

Global API Procurement Landscape

The sourcing of APIs for SYNALGOS-DC-A depends heavily on global chemical manufacturing hubs, regulatory standards, and supply chain stability. The following sections detail the dominant sources and key suppliers involved.

Major API Production Regions

1. China

China remains the most significant producer of APIs globally, accounting for over 40% of global supply, due to its expansive chemical manufacturing infrastructure, cost advantages, and scale efficiencies. Chinese API manufacturers often supply generic APIs such as Diclofenac and other NSAIDs.

Leading Chinese API Suppliers:
- Zhejiang Haining Fuchang Pharmaceutical Co., Ltd.
- Zhejiang Huahai Pharmaceutical Co., Ltd.
- Jiangsu Hanrui Pharmaceutical Co., Ltd.

Chinese manufacturers are often certified under international standards (e.g., cGMP, ISO), facilitating export to regulated markets.

2. India

India has established itself as a critical API manufacturing hub, supporting the global pharmaceutical industry with high-quality, cost-effective APIs. Indian suppliers frequently meet stringent regulatory standards, making them preferred sources for companies exporting to the US and Europe.

Major Indian API Suppliers:
- Sun Pharmaceutical Industries Ltd.
- Aarti Drugs Ltd.
- Lupin Ltd.
- Natco Pharma Ltd.

3. European Union and United States

While smaller in scale compared to China and India, EU and US-based manufacturers focus on high-grade APIs with strict adherence to regulatory compliance—particularly for markets demanding rigorous quality assurance.

European API Suppliers:
- EuroAPI (France)
- Siegfried AG (Switzerland)
US API Suppliers:
- Lonza Group
- Thermo Fisher Scientific

Key API Suppliers for SYNALGOS-DC-A

Given the formulation's nature, suppliers of Diclofenac sodium are most relevant. The choices depend on regulatory considerations, manufacturing standards, and cost factors.

1. Chinese Suppliers

Zhejiang Hengan Pharmaceutical Co. Ltd.
- Known for consistent quality and large-scale production.
- Compliant with international standards, including FDA, EMA, and WHO.
Qingdao Yiqing Pharmaceutical Co. Ltd.
- Certified for GMP; supplies Diclofenac sodium bulk API globally.

2. Indian Suppliers

Aarti Drugs Ltd.
- Provides high purity Diclofenac sodium APIs adhering to global regulatory standards.
Lupin Ltd.
- Has expansive API manufacturing capacity, with strong export credentials.

3. European and US Suppliers

EuroAPI
- Supplies high-quality APIs with comprehensive regulatory documentation suitable for strict markets.
Siegfried AG
- Offers bespoke APIs, including Diclofenac sodium, with emphasis on quality and regulatory compliance.

Regulatory Considerations

Suppliers must meet cGMP standards to ensure API quality and safety. Regulatory agencies, including the FDA, EMA, and PMDA, enforce compliance protocols. Many Chinese and Indian API suppliers have gained certifications, but companies should verify specific batch certifications, stability data, and quality assurance documents.

Current Market Trends

Shift Toward High-Quality Sources: Pharmaceutical companies increasingly prioritize suppliers with proven regulatory compliance and validated quality systems amid rising quality standards globally.
Supply Chain Diversification: To mitigate risks from regional disruptions, companies are broadening their supplier base across multiple regions.
Price and Quality Balance: The market continues to oscillate between cost-effective Chinese APIs and highly regulated European/US supplies, with some companies investing in dual sourcing strategies.

Supply Chain Challenges and Opportunities

Political and Trade Tensions: Tariffs, export restrictions, and geopolitical uncertainties affect API sourcing stability.
Regulatory Stringency: The increasing emphasis on regulatory compliance requires rigorous auditing and validation of suppliers.
Emerging Suppliers: New entrants from Southeast Asia and Latin America present potential alternatives but need verification of regulatory standards.

Conclusion

Reliable sourcing of the API for SYNALGOS-DC-A hinges on selecting suppliers with proven quality, regulatory compliance, and capacity to match production demands. Chinese and Indian API producers dominate the landscape, with European and US vendors offering high-grade options for regulated markets. Strategic diversification, continuous quality assurance, and adherence to international standards remain critical for ensuring uninterrupted supply and compliance.

Key Takeaways

Major API sources for SYNALGOS-DC-A include China, India, Europe, and the US, with Chinese and Indian manufacturers leading due to cost and capacity.
Diclofenac sodium remains the most common API for NSAID-based formulations within SYNALGOS-DC-A, sourced from multiple regional suppliers.
Regulatory compliance, such as cGMP certification, is essential to qualify API suppliers, especially for markets with strict standards like the US and Europe.
Supply chain diversification reduces vulnerability to regional geopolitical or logistical disruptions.
Emerging suppliers and regions offer new opportunities but require rigorous evaluation and compliance verification.

FAQs

1. What factors should pharmaceutical companies consider when sourcing API for SYNALGOS-DC-A?
Regulatory compliance, quality assurance, supplier certification, production capacity, cost, and supply chain stability.

2. Are Chinese API suppliers suitable for regulated markets?
Yes, many Chinese suppliers have attained certifications (e.g., cGMP, ISO) and export to regulated markets, but thorough audits and validation are recommended.

3. How can companies mitigate risks associated with API supply disruptions?
By diversifying suppliers across regions, establishing long-term contracts, and maintaining strategic inventory reserves.

4. What regulatory certifications are essential for API suppliers?
cGMP, ISO 9001, and region-specific certifications like FDA approval or EMA certification are critical.

5. Is it advantageous to source APIs from multiple regions?
Yes, multi-regional sourcing enhances supply security, regulatory compliance flexibility, and cost management.

Sources

[1] Global Industry Analysts, "API Market Analysis," 2022.
[2] U.S. Food and Drug Administration, "Guidance for Industry: APIs and CMC Data," 2019.
[3] European Medicines Agency, "API Manufacturing Standards," 2021.
[4] IQVIA Institute, "Global Active Pharmaceutical Ingredient Market," 2023.
[5] PharmaSource, "Top API Suppliers and Market Trends," 2022.

Bulk Pharmaceutical API Sources for SYNALGOS-DC-A